Search Bar & Filters
Found 41 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating two wound management methods for patients with severe open tibia fractures requiring multiple irrigation and debridement surgeries. This Phase III randomized controlled trial compares an antibiotic cement bead pouch to negative pressure wound therapy NPWT to see which better reduces complications such as infection, amputation, or delayed healing. This research aims to address uncertainties about optimal wound care between surgeries, led by the University of Maryland, Baltimore. Participants will be randomly assigned to receive either an antibiotic bead pouch or NPWT after their first irrigation and debridement surgery. The antibiotic bead pouch consists of non-absorbable antibiotic-laden cement beads placed in the wound and sealed with an occlusive dressing. NPWT involves a sealed dressing connected to a vacuum pump that applies negative pressure to promote healing. Treatment will continue between surgeries as needed, with adjustments made by the surgical team. Participants will be followed for six months after randomization, with assessments at 6 weeks, 3 months, and 6 months. Researchers will evaluate outcomes including mortality, lower limb amputation, unplanned reoperations, and fracture healing using the Functional IndeX for Trauma FIX-IT instrument. Safety events and outcomes will be reviewed by committees to monitor trial progress and participant well-being.
Actively Recruiting
Researchers are evaluating the safety, feasibility, and effectiveness of prolonged automated robotic transcranial Doppler TCD monitoring in critically ill patients with severe traumatic brain injury TBI. The study aims to assess this technology across multiple clinical sites with varying levels of TCD availability and experience to better understand its clinical utility. Participants will undergo daily sessions of automated robotic TCD monitoring for up to 4 hours each day, for a minimum of 3 days and up to 5 days when possible. The monitoring uses a robotic system with bilateral 2-MHz Doppler probes to continuously record cerebral blood flow velocity in both middle cerebral arteries. This system includes automated angle correction to maintain optimal measurement quality. During the study, participants will be monitored for safety concerns such as discomfort, device dislodgement, and skin changes at the probe site. Feedback will be collected from nurses and clinicians to evaluate safety and feasibility. Researchers will also assess the adequacy of temporal windows and insonation quality of the arteries. The total study duration includes up to 5 days of monitoring with ongoing safety and usability assessments.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating how products containing Chardonnay marc, combined with cocoa flavanols, affect heart and metabolic health. This research focuses on measuring how these products influence blood vessel function and related health markers, including the gut microbiome, in adult males aged 30 to 50. The study aims to gather data that will help design future dietary trials and understands how different product forms impact the bodys response, especially 6 hours after consumption when certain metabolites peak in the bloodstream. The study uses a randomized, double-blind, crossover design involving up to 5 participants. Each participant will consume different test products on separate occasions low flavanol cocoa powder, high flavanol cocoa powder, and various servings of Vine to Bar Chocolate containing both cocoa flavanols and Chardonnay marc, including a version with almonds. Responses will be measured after single intakes followed over 6 hours to compare effects across these products. Participants will undergo assessments including the Framingham Reactive Hyperemia Index fRHI at 6 hours, along with tests for platelet aggregation, oxidative enzymes, glucose, insulin, and nitrate levels. The study involves close monitoring of vascular and metabolic responses after product intake. Participants will follow all procedures and visit schedules as outlined, with the total involvement lasting for the duration of these acute testing visits.
Actively Recruiting
Researchers are evaluating how to best recommend chemotherapy for patients with colon cancer based on the presence or absence of circulating tumor DNA ctDNA after surgery. This Phase IIIII trial aims to determine if ctDNA can be used to better identify patients who need adjuvant chemotherapy and to assess optimal chemotherapy regimens for those with detectable ctDNA, as current biomarkers have not been prospectively validated. Participants are assigned to different groups based on their ctDNA status after surgery. Those without detectable ctDNA may undergo serial ctDNA monitoring without treatment or receive shorter chemotherapy regimens. Patients with detectable ctDNA receive more intensive chemotherapy options, including combinations of oxaliplatin, leucovorin, 5-fluorouracil, irinotecan, or capecitabine, administered intravenously or orally over cycles lasting several weeks. The study includes randomization and uses the Signatera test for central ctDNA detection. During the study, participants will undergo regular blood tests for ctDNA status, imaging scans, and clinical assessments. Researchers will track ctDNA positivity over up to 3 years and disease-free survival over up to 5 years. Other measures include overall survival, recurrence rates, and chemotherapy compliance. The total study duration may extend several years with ongoing monitoring to evaluate safety and treatment outcomes.
Actively Recruiting
Researchers are evaluating whether adding surgery to remove the kidney cytoreductive nephrectomy improves overall survival compared to immunotherapy-based drug combinations alone in patients with metastatic kidney cancer. This phase III trial focuses on patients with newly diagnosed metastatic renal cell carcinoma, exploring the effects of combining surgery with immunotherapies such as nivolumab, ipilimumab, pembrolizumab, and avelumab, along with axitinib, which may help slow tumor growth. Participants initially receive one of three standard immune checkpoint inhibitor-based regimens before randomization. After 10 to 14 weeks, eligible patients are randomly assigned to continue systemic immunotherapy with or without surgery to remove the kidney. Surgery may be performed within 8 weeks after randomization and can be done using laparoscopic, open, or robotic methods. Immunotherapies continue alongside axitinib unless surgery is planned, in which case axitinib is paused at least 24 hours before surgery. Throughout the study, participants undergo scans, physical exams, and laboratory tests to monitor tumor response and overall health. After treatment, patients are followed up every 3 months for the first year, then every 6 months for up to 3 years, and annually up to 7 years from randomization. The main measurement is overall survival, with additional assessments including tumor response, progression-free survival, treatment complications, and changes in tumor size at week 12. Specimens may be collected for future research.
Actively Recruiting
Researchers are evaluating a combination of pembrolizumab pembro, gemcitabine, vinorelbine, and liposomal doxorubicin GVD in patients with relapsed or refractory classic Hodgkin lymphoma cHL. This phase II, multicenter, open-label study aims to determine the complete response rate using both imaging and circulating tumor DNA ctDNA to assess minimal residual disease MRD and treatment response. The study also evaluates progression-free and overall survival, adverse events, and quality of life over time, with long-term follow-up for up to 5 years. Participants receive two 21-day cycles of pembrolizumab intravenously on day 1, alongside gemcitabine, vinorelbine, and liposomal doxorubicin administered intravenously on days 1 and 8 of each cycle. Pegfilgrastim is given for supportive care during each cycle. After two cycles, response is assessed by PETCT imaging and ctDNA testing using the Foresight CLARITY LDT platform. Based on response, participants may continue with additional pembrolizumab and GVD cycles, undergo non-transplant consolidation with pembrolizumab andor involved-site radiotherapy ISRT, or switch to salvage therapy and autologous stem cell transplant ASCT. Throughout the study, participants undergo periodic imaging and blood tests to monitor disease status, including PETCT scans and advanced ctDNA assessments. Patient-reported outcomes and quality of life are measured via standardized questionnaires. Safety monitoring includes tracking adverse events and immune-related effects. Participants are followed for up to five years to evaluate long-term outcomes and treatment effects, with the primary outcome focusing on complete response rate within four cycles of therapy.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating whether a natural product supplement can enhance collagen synthesis after ingesting collagen protein in young healthy adults aged 18 to 30 years. The study uses a model of natural products certified as safe to stimulate collagen synthesis and aims to see if the supplement increases the bodys collagen production response. This trial involves dietary supplements and focuses on connective tissue and exercise effects. Participants will consume either a natural product supplement containing hydrolyzed collagen, vitamin C, epicatechin, vitamin E, and stevia extract or a placebo supplement with hydrolyzed collagen, vitamin C, and sweetener. Blood samples are taken before and one hour after consumption. Participants will perform load-bearing exercise and take the assigned supplement daily for seven days, with a final blood collection four hours after the last exercise session. During the study, researchers will measure collagen protein synthesis over seven days and assess the strength and collagen content of engineered ligament constructs 60 minutes after exercise. Blood samples and exercise responses will be monitored to evaluate the supplements effects. The total participation period spans one week, with close monitoring of exercise and supplement intake under controlled conditions.
Actively Recruiting
Healthy Volunteer
Researchers are studying how early life experiences influence young childrens ability to delay gratification and how this behavior relates to later life outcomes. The study focuses on whether waiting experiences in early childhood predict delaying behavior in different situations, and how social customs, effort, and choices affect these links. The trial involves typically developing children aged 4 to 7 years and is sponsored by the University of California, Davis. Participants will take part in several activities across sessions. Children will complete delay of gratification tasks with either a sweet treat or a wrapped gift as rewards, assigned randomly. They will also perform games measuring inhibition, cognitive flexibility, and proactive control, including computerized tasks with eye-tracking using a camera. Parents will answer questionnaires about their childs behavior and experiences with waiting at home. One year after the initial sessions, participants and parents will repeat a subset of these assessments. During the study, researchers will measure multiple outcomes such as choice delay, executive function, social conventions, academic readiness, inhibitory control, cognitive flexibility, problem behaviors, and experiences waiting at home. They will also collect secondary data including pupil dilation, behavior during delaying, subjective effort, proactive control, and child temperament. The study involves initial and follow-up sessions over one year, with no blinding and randomized assignment to different delay tasks.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating a machine learning ML algorithm that combines pulse oximetry features, including oxygen saturation and perfusion measurements, to screen for critical congenital heart disease CCHD in newborns. This study aims to externally validate the algorithm previously tested internally, assessing if adding perfusion measures and repeated measurements improves detection accuracy and reduces false positives. Participants will have non-invasive oxygen saturation SpO2 and perfusion index PIx measured using pulse oximeters. The ML screening algorithm will analyze these measurements continuously, assigning predictions every minute. The study includes repeated measurements up to four times, including after 48 hours of age, which can be done outpatient. This approach supports creating a dynamic model that incorporates new data over time. During the study, newborns suspected of or undergoing screening for CCHD will have their SpO2 and PIx monitored. Researchers will collect data to evaluate the algorithms performance by measuring sensitivity, specificity, and the area under the receiver operating characteristic curve over approximately four years. Safety monitoring and follow-up are integrated into usual care with assessments through the newborn period up to 22 days of age.
Actively Recruiting
Healthy Volunteer
Researchers are investigating whether daily beef intake can help improve how zinc from the diet is absorbed into cells and support better metabolic and cardiovascular health in adults aged 55 to 70. This study focuses on older individuals who may have a higher risk of zinc deficiency and cardiovascular problems. The goal is to see if beef, as part of a heart-healthy diet, affects zinc-dependent processes that benefit blood vessel function. The study uses a randomized crossover design comparing two 4-week diet periods. One diet includes a beef stew providing 8.8 mg zinc and 37.9 mg protein, while the other uses a plant protein stew with the same zinc and protein content. Participants will switch between these diets to evaluate the effects of beef versus non-meat protein sources on zinc absorption and vascular health. Participants will undergo assessments of cellular zinc status using a novel zinc tracer in red blood cells and measurements of microvascular function through digital peripheral tonometry. Additional lab tests will monitor plasma lipids, fatty acids, and oxylipins. The study includes close dietary control and monitoring over the two 4-week periods, with outcomes focused on zinc uptake into cells and blood vessel health, lasting about 8 weeks in total.
1-10 of 41
1